Molecular Partners (MOLN) has released an update.
Molecular Partners AG is advancing its proprietary DARPin therapeutics, with significant progress in their Radio-DARPin Therapy platform, particularly the MP0712 candidate for treating neuroendocrine tumors, set to enter clinical trials in 2025. The company has also made strides with its MP0533 therapy for acute myeloid leukemia, showing promising clinical responses, and introduced the innovative Switch-DARPin platform, showcasing a novel ‘on/off’ mechanism for targeted immune responses. Financially, Molecular Partners is well-funded into 2027, expecting operating expenses between CHF 65-75 million for the year 2024.
For further insights into MOLN stock, check out TipRanks’ Stock Analysis page.
